New diesel fuel injector design could reduce soot, NOx emissions

This page is for personal, non-commercial use. You may order presentation ready copies to distribute to your colleagues, customers, or clients, by visiting http://www.autobloglicensing.com Diesel engines are extremely efficient  and produce loads of useful torque, but they also produce much high levels of NOx emissions and soot and other particulates that are harmful to the environment and people, which has dimmed their prospects, particularly in the wake of the recent diesel emissions cheating scandal. But the folks at Sandia National Laboratories Combustion Research Facility may have a way to drastically reduce the diesel engine’s pollutants, which could make diesel a more viable interim propulsion system again. The breakthrough lies in fuel-injector design. Sandia calls it ducted fuel injection, and compares the design to a Bunsen burner like you may have used in high school or college. How it works is that instead of the fuel injector spraying fuel straight into the open combustion chamber, there are ducts just outside the injector openings the fuel is sprayed through. The ducts are shaped such that as the fuel is sprayed into them, air is pulled in from the back of th...

selectION, Inc. Announces $4.1M Series A Investment

SAN DIEGO, May 31, 2019 /PRNewswire/ — http://selectiontherapeutics.com/ selectION, Inc., a biotherapeutic company focused on the development of peptide ion channel blockers with class leading selectivity, announced today it has received a $4.1M investment as first tranche of its Series A financing. New and existing investors include SDL Ventures and Global Source Ventures. “selectION has developed a powerful platform to design optimal blockers of ion channel targets with extremely high selectivity, the safety-limiting feature of molecules targeting ion channels.” said Antonius Schuh, PhD, Chief Executive Officer and Co-founder of selectION and a Managing Partner of Global Source Ventures. “With the funding received, we will complete pre-clinical development of si-544, a highly selective peptide blocker of Kv1.3, for the potential treatment of a wide range of effector-memory T cell (TEM) mediated diseases, including orphan and widespread autoimmune diseases and orphan oncology indications.”  The Company plans to initiate clinical development of si-544 by the end of 2020. About selectIONselectION, Inc., San Diego, is developing si-544, a highly sele...